Comparative Pharmacology
Head-to-head clinical analysis: LOW OGESTREL 21 versus TRI LO MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOW OGESTREL 21 versus TRI LO MILI.
LOW-OGESTREL-21 vs TRI-LO-MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive. Suppresses gonadotropin release (FSH and LH) via estrogen (ethinyl estradiol) and progestin (norgestrel), inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrium.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on the hypothalamic-pituitary axis; norgestimate binds to progesterone receptors, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily for 21 days, followed by 7 pill-free days.
One tablet orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Norgestrel: 18-28 hours; ethinyl estradiol: 13-27 hours. Steady-state achieved after 5-7 days.
Terminal elimination half-life: 20-24 hours; allows once-daily dosing for contraceptive efficacy.
Ethinyl estradiol and norgestrel are excreted primarily as glucuronide and sulfate conjugates in urine (50-60%) and feces (30-40%).
Renal: approximately 50% as metabolites; biliary/fecal: approximately 40% as metabolites; 10% unchanged in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive